Sanofi (NYSE:SNY) was upgraded by equities researchers at Barclays from an “underweight” rating to an “equal weight” rating in a research note issued on Wednesday, November 15th, Marketbeat Ratings reports.
A number of other equities research analysts also recently issued reports on SNY. raised shares of Sanofi from a “reduce” rating to a “hold” rating in a research note on Wednesday, August 30th. BidaskClub downgraded shares of Sanofi from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Sanofi in a research note on Friday, September 15th. Zacks Investment Research downgraded shares of Sanofi from a “hold” rating to a “strong sell” rating in a research note on Friday, October 6th. Finally, Argus reaffirmed a “buy” rating and set a $55.00 price target on shares of Sanofi in a research note on Friday, September 1st. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company’s stock. Sanofi currently has an average rating of “Hold” and a consensus price target of $53.50.
Sanofi (NYSE SNY) traded down $0.46 during mid-day trading on Wednesday, hitting $44.16. 1,538,472 shares of the stock traded hands, compared to its average volume of 1,504,267. Sanofi has a 1 year low of $38.45 and a 1 year high of $50.65. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.59 and a quick ratio of 1.16. The stock has a market capitalization of $112,509.69, a P/E ratio of 14.08, a PEG ratio of 2.46 and a beta of 0.86.
Hedge funds have recently bought and sold shares of the business. Fisher Asset Management LLC grew its holdings in shares of Sanofi by 3.3% in the third quarter. Fisher Asset Management LLC now owns 14,082,257 shares of the company’s stock worth $701,156,000 after purchasing an additional 443,799 shares during the last quarter. Founders Financial Securities LLC bought a new position in shares of Sanofi in the second quarter worth about $907,000. Goodwin Daniel L bought a new position in shares of Sanofi in the second quarter worth about $239,000. AMG National Trust Bank grew its holdings in shares of Sanofi by 5.3% in the second quarter. AMG National Trust Bank now owns 51,423 shares of the company’s stock worth $2,464,000 after purchasing an additional 2,594 shares during the last quarter. Finally, Alethea Capital Management LLC bought a new position in Sanofi during the 3rd quarter worth about $794,000. Institutional investors and hedge funds own 9.09% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This report was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/04/sanofi-sny-upgraded-by-barclays-plc-to-equal-weight.html.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.